What This Report Covers
This report covers the global market for cardiac rhythm management devices that deliver pacing or defibrillation without permanent intravascular leads or subcutaneous generator pockets. The scope includes single-chamber and dual-chamber leadless pacemakers, extravascular implantable cardioverter-defibrillators (EV-ICDs), extravascular defibrillation leads, delivery catheters, device programmers, remote monitoring platforms, procedural accessories, and investigational leadless conduction system pacing (CSP) platforms currently in clinical study. The report does not cover traditional transvenous pacemakers, conventional transvenous ICDs, cardiac resynchronization therapy (CRT) devices that do not use extravascular or leadless architecture, temporary pacing wires, or external defibrillation systems.Market Size and Forecast
The global Leadless Pacemaker and Extravascular ICD Market was valued at US$ 1,640 million in 2025 and is projected to reach US$ 7,920 million by 2032, expanding at a CAGR of 25.2% during 2026–2032.
| Metric | Value |
| Market Size, 2025 | US$ 1,640 million |
| Market Size, 2032 | US$ 7,920 million |
| CAGR, 2026–2032 | 25.2% |
| Largest Product Segment, 2025 | Single-Chamber Leadless Pacemakers |
| Fastest-Growing Product Segment | Dual-Chamber Leadless Pacemakers |
| Largest Application, 2025 | Bradyarrhythmia Management |
| Fastest-Growing Application | Dual-Chamber Pacing |
| Largest End-User Segment, 2025 | Hospitals and Electrophysiology Labs |
| Fastest-Growing End-User Segment | Specialty Cardiac Device Clinics |
| Largest Region, 2025 | North America |
| Fastest Strategic Growth Region | Asia-Pacific |
| Most Important Country Market | United States |
Why This Market Exists - And Why It Matters Now
The real question driving this market is simple: does every cardiac patient who needs pacing or defibrillation actually need a transvenous lead?For decades, the answer was assumed to be yes. Traditional pacemakers require a subcutaneous chest pocket for the generator, at least one lead threaded through a vein into the heart, and a system that stays in place for years. When it works, it works well. But the hardware burden accumulates. Transvenous leads fracture, dislodge, infect, obstruct venous pathways, cross the tricuspid valve, and create significant procedural complexity at replacement or extraction. Pocket infections can escalate into systemic device-related endocarditis. For certain patients - those on dialysis, those with prior device infections, those with limited venous access, those who are frail or immunocompromised, and young patients who will spend decades with their device - the conventional architecture carries a disproportionate long-term risk.
Leadless pacemakers remove the pocket and the lead entirely. A miniaturized pacing capsule is delivered directly into the right ventricle (or right atrium) via femoral catheter and anchors to the endocardium. Extravascular ICDs take a different approach: they keep the defibrillation lead outside the vasculature entirely, tunneled substernally, while still delivering defibrillation, cardioversion, and antitachycardia pacing (ATP) therapy.
Both technologies are commercially young but clinically proven. The market has moved past feasibility - it is now producing real-world evidence at scale. Medtronic's Enlighten Post-Approval Registry enrolled 787 patients and presented one-year outcomes at Heart Rhythm Society 2026 in Chicago in April 2026, demonstrating high ATP success, effective defibrillation, and a 95.8% freedom from chronic system-related major complications with the Aurora EV-ICD system. Abbott's Coverage with Evidence Development (CED) analysis, published in the Journal of Cardiovascular Electrophysiology (2026), compared 759 AVEIR DR patients against 77,422 dual-chamber transvenous pacemaker patients - and found a 41% lower rate of overall chronic complications in the leadless cohort. These are not feasibility signals. They are outcome data that electrophysiology programs use to justify protocol changes.
What is structurally different right now is that the patient eligibility question has broadened. Early leadless pacing was mostly reserved for patients with atrial fibrillation and slow ventricular response who needed only single-chamber ventricular pacing - a limited subset of the overall pacing population. Dual-chamber systems change the math significantly. Abbott has stated publicly that more than 80% of patients who need a pacemaker require two-chamber pacing. The FDA approval of AVEIR DR in July 2023 as the world's first dual-chamber leadless pacemaker opened that much larger population to a lead-sparing option. That single regulatory event is arguably the most consequential commercial inflection in this market's history.
Market Dynamics
What Is Driving Adoption
Complication avoidance is the primary clinical and economic driver
This is not a marketing claim - it is what physicians are increasingly quantifying. The European Heart Journal has published systematic review-level evidence that leadless pacemakers reduce infections, hematoma, pneumothorax, lead fracture, and lead dislocation versus conventional transvenous systems, with particular relevance in patients with diabetes, renal insufficiency, frailty, prior tricuspid valve intervention, or limited vascular access. A 2025 publication in Clinical Cardiology using the U.S. National Inpatient Sample showed that median hospitalization cost for leadless pacemaker implantation was approximately $34,098, and that complication-associated prolonged hospital stays were meaningfully less frequent than in transvenous cohorts. When hospitals and payers begin running total-episode cost analyses that account for avoided revisions, infection hospitalizations, and lead extraction procedures, the economic case for leadless systems strengthens considerably.The reimbursement architecture in the U.S. has matured enough to support broader use
CMS recognized the dual-chamber leadless pacemaker under its Inpatient Prospective Payment System (IPPS) with new technology add-on payments in 2024. The Heart Rhythm Society submitted advocacy to CMS in early 2024 to extend similar pass-through payment status to the outpatient setting under OPPS - a signal that the clinical community is actively working to reduce the cost-access gap that has historically limited these devices to high-acuity inpatient episodes. For FY2026, Medtronic's published Medicare rate tables show dedicated MS-DRG assignments for leadless pacemaker insertion, a maturation that signals sustained procedural volume.Dual-chamber functionality has structurally expanded the addressable market
The AVEIR DR system from Abbott uses proprietary i2i (implant-to-implant) wireless communication to synchronize beat-to-beat pacing between a separately implanted atrial device and a ventricular device - no transvenous leads connecting them. The one-year outcomes from the AVEIR DR i2i Study, published in Circulation: Arrhythmia and Electrophysiology in early 2025, showed consistent electrical performance and a low complication profile across 55 sites in the U.S., Canada, and Europe. For Japan specifically, AVEIR DR received insurance reimbursement approval in February 2025, and case reports from Chiba University Graduate School of Medicine published in the Journal of Arrhythmia in May 2025 have highlighted the clinical relevance for Japan's aging population.The Aurora EV-ICD creates a structurally new ICD category
The Aurora system received FDA approval in October 2023 as the only defibrillator with a substernal extravascular lead that simultaneously provides ATP therapy - something subcutaneous ICDs cannot offer. The Enlighten study's periprocedural data, published in Heart Rhythm (2025), showed substernal lead placement success in 227 of 228 patients (99.6%), with 96.9% proceeding to follow-up after electrical testing. The addition of real-world ATP success data - 74% in the Enlighten registry - and the absence of the chronic intravascular lead distinguishes Aurora from both conventional transvenous ICDs and subcutaneous ICDs. Medtronic presented updated Enlighten one-year data at HRS 2026 that showed a further reduction in inappropriate shock rates compared with the pivotal trial, an outcome that has historically been one of the clinical community's chief concerns with novel ICD sensing configurations.What is Slowing Adoption
The economic hurdle at the point of hospital procurement remains real
Leadless pacemakers and EV-ICDs carry a device cost premium versus conventional transvenous systems. Under Medicare's MS-DRG payment structure, a single payment covers all supplies and procedures for the entire inpatient stay. If the device cost consumes a disproportionate share of that payment, hospital economics create pressure against broad routine use. This is not a theoretical concern - it is one of the documented reasons that leadless pacing adoption has been concentrated in higher-complexity patient subgroups and tertiary referral centers. The challenge is not whether the technology works; it is whether the reimbursement structure adequately reflects the value of complications avoided.Patient selection requires more clinical judgment than conventional implantation
Leadless pacing is not appropriate for patients who need cardiac resynchronization therapy, those with complex pacing requirements that exceed current leadless platform capabilities, or those in whom the substernal anatomy makes EV-ICD implantation difficult or impossible - for example, patients with prior sternotomy. Medtronic's current clinical guidance positions Aurora EV-ICD as a first-line option specifically for patients without prior sternotomy and without chronic pacing indications. Narrowing eligibility criteria at launch is standard practice for novel platforms, but it does slow initial adoption curves.Long-term device management questions are not fully answered
Retrieval, end-of-service replacement, battery exhaustion strategy, and the management of a patient with multiple accumulated leadless devices over decades of therapy remain areas where real-world data are still accumulating. Through nine years, the AVEIR VR predecessor device shows an 88% long-term retrieval success rate using its active fixation helix mechanism - a meaningful result, but one that still means 12% of cases pose retrieval complexity. Medtronic's Micra AV2 offers approximately 16 years of projected median battery life, and Micra VR2 approximately 17 years - which pushes the replacement decision further out, but does not eliminate it. For younger patients implanted in their 40s or 50s, the lifetime device management question carries real clinical weight.By Product Segmentation
Single-Chamber Leadless Pacemakers - US$ 760M (2025) → US$ 2,520M (2032)
Single-chamber devices represent 46.3% of the 2025 market and are led by Medtronic's Micra family and Abbott's AVEIR VR. These devices are used primarily in patients with atrial fibrillation and bradycardia - patients for whom AV synchrony is not the priority because atrial fibrillation already eliminates coordinated atrial-ventricular timing. Micra AV2 and VR2 received FDA approval in May 2023, with battery life projections of nearly 16 and 17 years respectively - roughly a 40% improvement over previous generations. This matters because battery longevity directly affects the frequency of replacement procedures and is a key factor in physician-patient discussions about long-term device management. Abbott's CED study comparing AVEIR VR against single-chamber transvenous pacemakers, using Medicare fee-for-service data from 2022 to 2024, found that the leadless device delivered lower complication rates nearly immediately after commercialization. This segment will remain the revenue foundation but will gradually lose share as dual-chamber adoption scales.Dual-Chamber Leadless Pacemakers - US$ 360M (2025) → US$ 2,650M (2032)
This is the fastest-growing product segment in the market, and the reason is straightforward: it addresses where most pacemaker patients actually need care. Abbott's AVEIR DR system, approved by the FDA in July 2023 and commercially available in the U.S. from November 2023, provides true beat-to-beat synchronized atrial and ventricular pacing through two separate leadless devices communicating wirelessly via i2i technology. Commercial implant experience across 8 U.S. centers in 175 patients showed 99% complication-free outcomes at 30 days. The real-world CED analysis covering 759 AVEIR DR patients versus 77,422 transvenous dual-chamber patients - presented at the Asia Pacific Heart Rhythm Society 2025 meeting - demonstrated a 41% lower rate of overall chronic complications, with comparable mortality. Japan's insurance reimbursement for AVEIR DR in February 2025 is an early marker of how major markets outside the U.S. are moving toward adoption.Extravascular ICD Systems - US$ 430M (2025) → US$ 2,270M (2032)
Medtronic's Aurora EV-ICD system, approved by the FDA in October 2023, holds the only commercial position in this segment. The device places a substernal lead that runs from a left-sided generator, through a tunnel under the sternum, to the anterior mediastinum - entirely outside the bloodstream. It detects ventricular arrhythmias, delivers defibrillation, and provides post-shock and anti-tachycardia pacing in a single implanted system. The final results from the Pivotal EV-ICD study, published in Circulation in early 2025, showed long-term follow-up confirming sustained safety and efficacy. The Enlighten real-world registry, now covering 787 patients, presented one-year outcomes at HRS 2026 showing 100% defibrillation success for discrete spontaneous episodes through the latest follow-up, 74% ATP success, 95.8% freedom from chronic system-related major complications at one year, and a further reduction in inappropriate shock rates versus the pivotal trial. The periprocedural data published in Heart Rhythm shows substernal lead placement was successful in 99.6% of patients. The segment will grow as EV-ICD training programs expand, procedural confidence improves, and more electrophysiology centers establish volume-based familiarity with the substernal tunneling technique.Emerging Leadless Conduction System Pacing Platforms - US$ 90M (2025) → US$ 480M (2032)
This is the strategically most significant segment for the next decade. Conduction system pacing targets the heart's intrinsic electrical conduction pathways - particularly the left bundle branch area - to deliver physiologic, synchronous activation rather than the right ventricular apical pacing that conventional transvenous and single-chamber leadless systems provide. The clinical advantage is that physiologic pacing avoids the dyssynchrony associated with right ventricular stimulation, which over years can impair left ventricular function in a meaningful proportion of patients.Abbott has FDA Breakthrough Device Designation for its AVEIR CSP leadless pacemaker system. The world's first human leadless left bundle branch area pacing (LBBAP) procedures were completed by Dr. Petr Neužil at Na Homolce Hospital in Prague and Dr. Vivek Reddy at Mount Sinai Hospital in New York in late 2024, as part of the prospective Leadless CSP feasibility study. Late-breaking data from this study was presented at HRS 2025 in San Diego in April 2025, confirming successful implantation deep into the interventricular septum and achievement of LBBAP in a meaningful proportion of participants. A first-in-human evaluation of the next iteration of AVEIR CSP was presented at HRS 2026 in April 2026. Abbott has also initiated enrollment in the ASCEND CSP pivotal trial, evaluating an investigational CSP ICD lead that will enroll up to 414 patients across 70 global sites. BIOTRONIK's LivIQ system takes a different technical path - electrical far-field sensing of atrial activity to enable single-device VDD pacing - with first-in-human implants completed in Australia in January 2026 and the global BIO-LivIQ pivotal study underway as of March 2026, enrolling 325 patients across 60 sites. Current market revenue in this segment reflects early institutional implants, clinical trial activity, and nascent commercial traction where approved versions of related technology exist.
By Application Segmentation
Bradyarrhythmia Management (US$ 690M in 2025 → US$ 2,660M by 2032) remains the largest application, representing 42.1% of 2025 revenue. This is where leadless pacemakers have the longest commercial track record - single-chamber ventricular pacing in patients with atrial fibrillation and slow ventricular response, intermittent atrioventricular block, or sinus node dysfunction with limited pacing burden.Dual-Chamber Pacing (US$ 330M → US$ 2,480M) is the fastest-growing application, expanding from 20.1% of 2025 revenue. The AVEIR DR approval is the catalyst, but sustained growth depends on continued real-world evidence, physician training program maturity, and reimbursement clarity in outpatient and ambulatory settings.
Sudden Cardiac Death Prevention (US$ 460M → US$ 2,190M) includes patients who need defibrillator therapy but may derive clinical benefit from avoiding an intravascular defibrillation lead. This application is growing as EV-ICD data matures and as the clinical community gains procedural experience with the substernal tunneling approach required for Aurora EV-ICD implantation.
High-Risk Infection and Limited Vascular Access Cases (US$ 160M → US$ 590M) are smaller in revenue but represent the highest density of clinical justification for premium leadless devices. The i-LEAPER registry, published in Heart Rhythm in 2025, specifically analyzed leadless pacemakers in patients with chronic kidney disease - a population with elevated infection and vascular complication risk - and reported results that support routine use in this group. For dialysis patients, patients with prior device infection, and immunocompromised patients, the clinical case for avoiding transvenous hardware is often the clearest of any patient group.
By End-User Segmentation
Hospitals and Electrophysiology Labs (US$ 1,050M → US$ 4,780M) are and will remain the dominant implanting setting. Leadless pacemakers and EV-ICD implantation require fluoroscopy, vascular access management, intracardiac electrogram assessment, trained implanters, and recovery infrastructure. High-volume programs are essential for technique consistency, complication recognition, and procedural learning curves.Academic and Training Centers (US$ 230M → US$ 1,130M) play a disproportionately important role in the development trajectory of this technology. Evidence generation for AVEIR CSP, EV-ICD long-term performance, and BIOTRONIK LivIQ is concentrated at academic sites. These centers also drive the institutional protocols, training curricula, and complication management experience that diffuse into community practice over time.
Ambulatory Cardiac Centers (US$ 210M → US$ 1,080M) are gaining ground as single-chamber leadless pacemaker procedures become standardized. The movement of lower-acuity implants to efficient outpatient settings follows a pattern seen across many device categories - as techniques mature, volume migrates to cost-efficient venues. This migration depends on CMS OPPS reimbursement decisions, which the Heart Rhythm Society has been actively advocating on.
Specialty Cardiac Device Clinics (US$ 150M → US$ 930M) are the fastest-growing end-user segment. As implanted populations grow, follow-up infrastructure becomes a commercial category in its own right. These clinics handle device programming, battery surveillance, remote monitoring review, arrhythmia alerts, and long-term patient education. The economic model for specialty cardiac device clinics will become increasingly important as the number of patients living with leadless and extravascular devices accumulates through the decade.
Regional Analysis
North America - US$ 810M (2025) → US$ 3,560M (2032)
North America accounts for 49.4% of global revenue in 2025 and will remain the largest market through 2032. The United States specifically generated US$ 735M in 2025 and is projected at US$ 3,210M by 2032. The U.S. has the deepest implanting infrastructure for cardiac rhythm management, the most mature reimbursement pathway for leadless pacing (through CMS Coverage with Evidence Development), and the earliest FDA approvals for both Aurora EV-ICD and AVEIR DR. The competitive dynamics in the U.S. are intense - Medtronic and Abbott are engaged directly, with every major clinical trial, registry study, and real-world evidence publication anchored in U.S. data.One underappreciated structural trend in the U.S. market: the rural-urban divide in leadless pacemaker adoption. A 2025 analysis in Clinical Cardiology using the National Inpatient Sample compared leadless device implantations in rural versus urban hospitals and found meaningful differences in complication rates, length of stay, and hospitalization costs - driven primarily by volume-outcome relationships at implanting institutions. This is creating a geographic access problem that neither CMS reimbursement policy nor manufacturer training programs have fully addressed. Large referral centers in metropolitan areas are building procedure volume. Rural and community hospitals - where a significant portion of the U.S. pacing population actually receives care - remain in early adoption phases, partly due to limited implanter experience and partly due to hospital procurement economics.
Europe - US$ 510M (2025) → US$ 2,420M (2032)
Europe represents 31.1% of global revenue and is primarily an evidence-sensitive market where reimbursement decisions follow clinical outcomes rather than precede them. Medtronic received CE Mark for Micra AV2 and VR2 in January 2024. Germany, France, the United Kingdom, Italy, Spain, the Netherlands, and the Nordic countries are the major revenue contributors.Germany (US$ 155M → US$ 760M) is the largest European market and the most procedure-volume intensive. Germany's DRG-based hospital reimbursement system tends to favor technologies that demonstrably reduce length of stay or complication-associated readmissions - which is exactly what leadless pacemaker evidence is beginning to show. France (US$ 105M → US$ 510M) operates through a more centralized HTA process, and adoption has historically been concentrated in CHU (university hospital) settings before diffusing to regional centers. The clinical justification for leadless pacing in elderly French patients with multiple comorbidities - an analytically important subset of the country's pacing population - is being built out through single-center registries.
Asia-Pacific - US$ 320M (2025) → US$ 1,940M (2032)
Asia-Pacific represents 19.5% of 2025 revenue and is the fastest strategic growth region, though the pace of adoption is highly country-specific rather than region-wide.Japan (US$ 115M → US$ 720M) is the most clinically advanced Asia-Pacific market for leadless technology. The Micra system has been commercially available since 2017 and has a well-established track record in Japan's aging population. AVEIR DR received insurance reimbursement in February 2025 - earlier than many anticipated for a recently approved dual-chamber system - reflecting Japan's Sakigake designation framework, which accelerates review for innovative devices addressing unmet clinical needs. Japan is also a global first-mover in BIOTRONIK's LivIQ pivotal study, with initial implants at Kokura Memorial Hospital in Kitakyushu and the National Cerebral and Cardiovascular Center in Osaka in March 2026. The investigators from these institutions have publicly noted the system's handling characteristics and AV-synchrony performance in early implants.
China (US$ 120M → US$ 760M) represents the largest long-term volume opportunity but is not the fastest current adopter. Adoption is concentrated in Tier 1 and Tier 2 hospital centers in Beijing, Shanghai, Guangzhou, and a small number of provincial capitals. NMPA regulatory approvals, National Reimbursement Drug List inclusion, and the health technology assessment processes that determine whether premium devices receive adequate reimbursement at scale remain the primary gating factors. Local manufacturers are beginning to develop leadless pacing programs - Shenzhen Lifetech Scientific, which has domestic Chinese EP device expertise, has been noted in device market analyses as a potential long-term entrant - but no domestic leadless pacemaker has yet achieved the clinical validation scale of Medtronic or Abbott's platforms. Multinational companies will maintain premium positioning in China's market, but pricing pressure will intensify as the decade progresses.
South Korea (US$ 38M → US$ 240M) is a higher-income, technology-forward market where advanced cardiac rhythm management devices gain traction in tertiary centers ahead of broader rollout. The Health Insurance Review and Assessment Service (HIRA) process governs reimbursement and will be the key variable in determining whether adoption moves beyond academic centers into community hospitals.
India received AVEIR VR regulatory clearance in 2024, according to published market data. Adoption at scale in India faces significant challenges around device affordability, the concentration of interventional cardiology infrastructure in private urban hospitals, and insurance coverage. High out-of-pocket costs for medical devices mean that leadless pacemaker use will be concentrated in a relatively small segment of the Indian cardiac device market - premium private hospitals and selected government institutions with access to external funding or subsidy programs.
Australia is smaller in absolute revenue but strategically important as a first-mover clinical market. The world's first human LivIQ leadless pacemaker implants under the BIO|CONCEPT.LivIQ premarket study were performed in Brisbane at Princess Alexandra Hospital and in Melbourne at Victorian Heart Hospital in January 2026, making Australia the site of a globally significant clinical milestone.
Competitive Landscape
Medtronic
Medtronic holds the strongest current commercial position in this market - the only company with both an established leadless pacemaker franchise (Micra) and an FDA-approved EV-ICD system (Aurora). The Micra platform created the commercial category for leadless pacing starting with the original Micra TPS, and each subsequent generation has extended battery life, expanded programming capability, and broadened the clinical indications. Micra AV2 projects approximately 16 years of median battery life; Micra VR2 projects approximately 17 years - both about 40% beyond the prior generation.Aurora EV-ICD is a platform that no competitor currently challenges commercially. The substernal lead technology, the ATP capability, and the growing real-world evidence base from the Enlighten registry collectively create a defensible position. Medtronic has also received FDA approval for placing its OmniaSecure transvenous defibrillation lead in the left bundle branch area (approved for LBBA placement in 2026) - which shows that the company is competing in the conduction system pacing space not only through future leadless platforms but through its existing lead portfolio.
The strategic question for Medtronic is whether it can maintain the EV-ICD category lead while Abbott moves into next-generation conduction system pacing and BIOTRONIK builds a competing single-device AV-synchrony approach.
Abbott
Abbott's position is built on AVEIR DR's structural advantage - being first to market with a dual-chamber leadless system positions it in the largest segment of the pacing population. The 41% reduction in chronic complications versus transvenous dual-chamber pacemakers, from real-world Medicare data, is a data point that changes hospital protocol conversations. Abbott has also shown strategic breadth: the AVEIR CSP program, which received FDA Breakthrough Device Designation, is the world's first leadless pacemaker system designed to deliver left bundle branch area pacing. The first-in-human LBBAP procedures completed in late 2024 and the feasibility data presented at HRS 2025 represent Abbott's early claim on the next major frontier in pacing therapy - physiologic activation without transvenous leads.The ASCEND CSP pivotal trial, enrolling up to 414 patients across 70 global sites, will generate the regulatory-grade evidence needed to advance the CSP ICD lead. Both the AVEIR CSP leadless pacemaker and the CSP ICD lead have Breakthrough Device Designation, which provides FDA's most accelerated review pathway for novel device technologies.
BIOTRONIK
BIOTRONIK is the most credible investigational challenger in the leadless pacing segment. LivIQ uses electrical far-field sensing - an extension of BIOTRONIK's established DX technology - to detect atrial activity and enable single-device VDD pacing. The distinction matters clinically: where AVEIR DR requires two separately implanted leadless devices to achieve dual-chamber coordination, LivIQ proposes to achieve AV synchrony with a single implant by sensing the atrial signal from within the ventricle. If the pivotal study validates this approach across a broad clinical population, it would represent a meaningful engineering advantage - one device doing the work of two, with a lower total hardware burden and potentially simpler implant workflow.BIOTRONIK CTO Andreas Hecker has described LivIQ as bringing together "far-field sensing for AV synchrony and a highly maneuverable catheter for procedural confidence" - the two clinical concerns that most influence adoption in new-to-leadless implanting centers. First implants in the BIO-LivIQ pivotal study (325 patients, 60 sites globally) were completed at leading Japanese centers in March 2026, with enrollment ongoing.
Boston Scientific
Boston Scientific does not currently have a commercial leadless pacemaker or EV-ICD product. It remains relevant to this market through its deep customer relationships in electrophysiology and ICD programming, its subcutaneous ICD franchise (EMBLEM S-ICD), and its potential to enter through future product development, platform acquisition, or competitive response as the market grows. Its current IPPS reimbursement documentation acknowledges leadless pacemaker payment rates for informational purposes - a signal that it is monitoring the category carefully.What This Market is Actually About - Analyst Perspective
The commercial logic here is more specific than "cardiac devices are growing." What this market represents is the early stage of a systematic question being asked across cardiac electrophysiology: which part of the conventional device architecture is actually necessary for which patient?For a patient in atrial fibrillation with a slow ventricular rate, a single-chamber leadless pacemaker already answers the question completely - no lead, no pocket, no long-term transvenous hardware. For a patient who needs both chambers paced, AVEIR DR's real-world complication data is beginning to answer the same question for the dual-chamber population. For a patient at high risk of sudden cardiac death who does not need chronic pacing support, Aurora EV-ICD now answers that question for defibrillation.
The next question - whether a patient who needs physiologic, conduction system-level pacing can receive it without a transvenous lead - is what the AVEIR CSP and BIOTRONIK LivIQ programs are beginning to answer. That question is not yet commercially resolved, but it represents the clearest growth runway in the category.
Three linked problems determine which companies win: miniaturization to the point where devices are implantable without vascular access, physiologic performance that matches or exceeds conventional hardware, and long-term manageability that gives physicians and patients confidence in decades-long device strategy. The companies best positioned to capture value in this market are those that can demonstrate all three - not just at initial approval, but through the kind of real-world longitudinal evidence that changes standard-of-care protocols.
Recent Developments
- April 2026 - Medtronic presented one-year Enlighten Post-Approval Registry results at HRS 2026 in Chicago, covering 787 patients implanted with the Aurora EV-ICD system. The data showed high ATP success, effective defibrillation in 100% of discrete spontaneous episodes through latest follow-up, and 95.8% freedom from chronic system-related major complications - while also demonstrating a reduced inappropriate shock rate compared with the pivotal trial.
- April 2026 - Abbott presented late-breaking data at HRS 2026 from a first-in-human evaluation of the investigational AVEIR CSP leadless pacemaker system, marking the next phase of clinical development following the December 2024 first-in-human LBBAP procedures. Abbott also highlighted new data from the ASCEND CSP pivotal trial for its investigational UltiSynq CSP ICD lead.
- March 2026 - BIOTRONIK announced the initiation of the global BIO-LivIQ pivotal study, with first implants at Kokura Memorial Hospital in Kitakyushu and the National Cerebral and Cardiovascular Center in Osaka, Japan. The trial will enroll 325 patients across 60 sites globally to generate the clinical evidence needed for worldwide regulatory submissions.
- February 2025 - AVEIR DR received insurance reimbursement approval in Japan, marking a major market entry milestone for the world's first dual-chamber leadless pacemaker outside the United States and Europe.
- January 2026 - BIOTRONIK completed the world's first human implantations of LivIQ - the first intracardiac pacemaker to use atrial electrical far-field sensing for AV-synchronous pacing - in Australia.
- November 2025 - Six-month Enlighten results presented at APHRS in Yokohama showed consistent Aurora EV-ICD performance, with high ATP success and defibrillation efficacy in the real-world post-approval setting.
- January 2024 - Medtronic received CE Mark for Micra AV2 and VR2 in Europe, expanding access to next-generation leadless pacing with extended battery life across the European market.
Strategic Outlook to 2032
By 2032, the question is not whether this market will grow - the clinical evidence, regulatory infrastructure, and commercial investments are already in place to support the US$ 7,920M projection. The question is which clinical segments will lead, which geographies will close the adoption gap most quickly, and which technologies will shift the competitive hierarchy.Single-chamber leadless pacemakers will remain a high-volume revenue base. Dual-chamber leadless pacing will grow the fastest, because the eligible patient population is three to four times larger than for ventricular-only pacing. Extravascular ICD will carve out a durable position for patients who need defibrillation without an intravascular lead - a particularly important option for younger patients and for patients with prior lead or pocket complications who are being managed for sudden cardiac death risk. Leadless conduction system pacing, when it reaches commercial scale, will compete for patients who currently receive His-bundle or left bundle branch pacing through transvenous leads - a meaningful clinical population with strong physiologic rationale for the leadless approach.
North America will maintain its revenue leadership through premium device pricing, mature reimbursement, and concentrated implanting infrastructure. Asia-Pacific - and Japan specifically - will be the most active region for clinical evidence generation and early commercial scaling of next-generation platforms. China's market will track regulatory and reimbursement development rather than premium adoption dynamics. Europe will reward technologies that demonstrate health system-level value through complication and readmission reduction, with national reimbursement pathways determining the pace of adoption country by country.
The companies that will define this market by 2032 are those building device ecosystems - not just single products. Remote monitoring infrastructure, retrieval and replacement protocols, training programs for first-time implanters at community hospitals, and real-world evidence pipelines that extend well beyond initial approval will separate category leaders from devices that remain niche.